ABIONYX Pharma: Clarification About Clinical Results From the Phase 3 of apoA-I study, CSL112
16 Febrero 2024 - 1:10AM
Business Wire
Regulatory News:
Following numerous calls received since the press release of
February 15, 2024, ABIONYX Pharma (FR0012616852 - ABNX -
eligible for PEA PME) (Paris:ABNX), intends to clarify that the
Phase 3 clinical results for CSL112 are extremely positive for the
company's development and future.
They confirm:
- the company's successful strategic repositioning 4 years ago
outside the field of cardiovascular diseases
- the safety and tolerability of a treatment with apoA-1 in an
unprecedented clinical trial involving 18,000 patients
- the clarification of the regulatory horizon for the selected
development of ABIONYX Pharma's only recombinant human apoA-I
outside the field of cardiovascular diseases. Over the past 4
years, the company has filed numerous patents in renal and
ophthalmological diseases, extending the exclusivity of apoA-I
until 2043.
ABIONYX Pharma warmly thanks its loyal shareholders over the
past 4 years for their support since the company's successful
repositioning outside cardiovascular diseases, and for their keen
interest and requests for clarification of the company's scientific
and strategic communication.
About ABIONYX Pharma
ABIONYX Pharma is a next-generation biotech company focused on
developing innovative medicines in diseases where there is no
effective or existing treatment, even the rarest ones. The company
expedites the development of novel therapeutics through an
extensive expertise in lipid science and a differentiated apoA-I
-based technology platform. ABIONYX Pharma is committed to
radically improving treatment outcomes in sepsis and critical
care.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240215270551/en/
NewCap Investor relations Nicolas Fossiez Louis-Victor
Delouvrier abionyx@newcap.eu +33 (0)1 44 71 98 53
NewCap Media relations Arthur Rouillé abionyx@newcap.eu
+33 (0)1 44 71 00 15
Abionyx Pharma (EU:ABNX)
Gráfica de Acción Histórica
De May 2024 a Jun 2024
Abionyx Pharma (EU:ABNX)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024